Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

REACTION

Financiado

Cerrado

Evaluation of the efficacy and of the antiviral activity of T 705 favipiravir...

Evaluation of the efficacy and of the antiviral activity of T 705 favipiravir during Ebola virus infection in non human primates humans The ongoing Ebola outbreak in West Africa is the largest and deadliest the world has ever seen. In September 2014, the number of EBOV cases exceeded the total of all cases from previous known outbreaks. Further, this public health... ver más

31/10/2017

INSERM

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 14 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2017-10-31

DIGITAL-2024-CLOUD-AI-06-HEALTHRECORD: Demonstrating the in-service use of... Expected Outcome:Deliverables

I+D

Cerrada hace 8 meses

0% 93% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

14 Participantes

INSERM

1.24M€ | Lider

AMU

88.50K€ | Participante

4.25K€ | Participante

BNI

64.25K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PID2020-112895RB-I00 HACIA EL DESARROLLO DE ANTIVIRALES DE AMPLIO ESPECTRO DIRIGI... 163K€ Cerrado

PEVIA PAN EBOLA VACCINE INNOVATIVE APPROACH Sofia ref. 116088 18M€ Cerrado

FLUCURE Development of novel antiviral drugs against Influenza 8M€ Cerrado

ANTIFLU Innovative anti influenza drugs excluding viral escape 8M€ Cerrado

FluAttack Validation of a novel antiviral drug candidate against influ... 150K€ Cerrado

PANVIPREP Developing broad-spectrum antiviral drugs for pandemic prepa... 8M€ Cerrado

Duración del proyecto: 34 meses Fecha Inicio: 2014-12-03
Fecha Fin: 2017-10-31

Líder del proyecto

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The ongoing Ebola outbreak in West Africa is the largest and deadliest the world has ever seen. In September 2014, the number of EBOV cases exceeded the total of all cases from previous known outbreaks. Further, this public health crisis shifted into a complex emergency, with significant, social, economic, humanitarian, political and security dimensions. Till date, no effective medicine has been proven to be effective against EBOV. As a result, it is immensely difficult to mitigate the current outbreak as well as prevent further outbreaks in this region. On Sept 4-5 2014, the WHO gathered expertise on experimental therapies and vaccines and their role in containing the Ebola outbreak in West Africa. During this consultation, experts identified several therapeutic and vaccine interventions that should be the focus of priority evaluation. Among these candidates is the existing antiviral drug Favipiravir, that has proven activity against many RNA viruses in vivo and in vitro including Ebola. Favipiravir is known to inhibit viral gene replication within infected cells to prevent propagation among which it inhibits viral gene replication within infected cells to prevent propagation. Hence, Favipiravir is currently aimed as a curative option in severe pandemic flue. Furthermore, there is currently enough stock of Favipiravir to even treat more than 20.000 patients, and the producer of Favipiravir, Toyoma Chemical/Fujifilm in Japan is willing to rapidly upscale the production of this drug. This drug has been extensively tested in humans and approved in Japan for treatment and prevention of influenza. The drug has shown an excellent safety profile in more than 2000 patients tested and no major adverse effect were reported. The current crisis requires both an immediate response to treat patients and prevent the further spread of the epidemic, as well as long term commitment in the complex sociocultural context. REACTION! will address both needs.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores